Leukine (sargramostim) / Partner Therap 
Welcome,         Profile    Billing    Logout  

74 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukine (sargramostim) / Partner Therap
GRACE, NCT03769844 / 2007-001586-15: GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study

Active, not recruiting
4
120
US
GM-CSF, granulocyte macrophage colony-stimulating factor, Leukine
Nationwide Children's Hospital
Pediatric Sepsis-induced MODS
12/23
12/23
NCT00026312: Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Active, not recruiting
3
1449
Canada, US, RoW
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
01/12
03/25
SWOG-E4697, NCT00005034: Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma

Active, not recruiting
3
800
NA
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide, adjuvant therapy
Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Southwest Oncology Group
Intraocular Melanoma, Melanoma (Skin)
 
 
2014-001894-15: Administration de GRanulocyte–Macrophage Colony-stimulating Factor (GM-CSF) pour diminuer les Infections acquises en réanimation au cours de l’immunoDépression induite par le sepsis.Etude multicentrique randomisée en double aveugle contre placebo

Ongoing
3
488
Europe
Lyophilisate and solvent for solution for injection, Leukine
Hospices Civils de Lyon, Ministere de la santé
sepsis sévère ou choc septique dans les 24 premières heures de présence en réanimation, choc septique, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
REGAL, NCT04229979 / 2019-004134-42: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active, not recruiting
3
128
Europe, US, RoW
Galinpepimut-S, SLS-001, GPS, Azacitidine, Venetoclax, Decitabine, Cytarabine, Ara-C, Observation, GM-CSF, sargramostim, Montanide
Sellas Life Sciences Group
Acute Myeloid Leukemia
12/24
03/25
NCT03126916: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Active, not recruiting
3
724
Canada, US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dexrazoxane Hydrochloride, Cardioxane, Totect, Zinecard, Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide Phosphate, Etopophos, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Iobenguane I-131, (131)I-MIBG, 131I-MIBG, I 131 Meta-iodobenzylguanidine, I-131 Metaiodobenzylguanidine, Iobenguane (131I), Iobenguane I 131, Iodine I 131 Metaiodobenzylguanidine, MIBG I-131, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, Lorviqua, PF-06463922, Melphalan Hydrochloride, Alkeran, Alkerana, Evomela, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Therapeutic Conventional Surgery, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Neuroblastoma
09/26
09/26
NCT02339571: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Recruiting
2/3
600
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Elastography, MRE, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
06/33
06/33
NCT00466115: A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies

Not yet recruiting
2
18
US
MS-275, GM-CSF
Johns Hopkins University
Myelodysplastic Syndrome, Acute Myeloid Leukemia
 
04/07
NCT00060164: Rituximab, Autologous Vaccine Therapy, and Sargramostim in Treating Patients With Recurrent or Refractory Follicular B-Cell Lymphoma

Active, not recruiting
2
US
autologous immunoglobulin idiotype-KLH conjugate vaccine, rituximab, sargramostim
University Hospitals Seidman Cancer Center, National Cancer Institute (NCI)
Lymphoma
 
 
2012-002272-14: An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Studio internazionale randomizzato, in doppio cieco, controllato, di fase II con Rindopepimut/GM-CSF e temozolomide in terapia adiuvante in pazienti con glioblastoma EGFRvIII-positivo sottoposto a resezione chirurgica, di diagnosi recente.

Ongoing
2
140
Europe
Rindopepimut, KLH, CDX-110, NA, Concentrate for solution for injection/infusion, Sargramostim
CELLDEX THERAPEUTICS, Celldex Therapeutics, Inc.
Newly diagnosed, surgically resected, EGFRvIII-positive Glioblastoma Pazienti con glioblastoma EGFRvIII-positivo sottoposto a resezione chirurgica, di diagnosi recente, Newly diagnosed, surgically resected, EGFRvIII-positive Glioblastoma pazienti con glioblastoma EGFRvIII-positivo sottoposto a resezione chirurgica, di diagnosi recente, Diseases [C] - Cancer [C04]
 
 
NCT01134614: Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Checkmark ASCO 2013
Jun 2013 - Jun 2013: ASCO 2013
Active, not recruiting
2
245
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
02/13
03/25
2006-006212-30: A Randomised, Open labelled, Phase II, Immunogenicity, and Exploratory Efficacy Evaluation of Therapeutic Immunisations +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly Active Anti-retroviral Therapy (HAART).

Ongoing
2
30
Europe
Saizen, IR103, Proleukin, Leukine, IR103 is a combination of Remune and Amplivax, Saizen, Proleukin, Leukine, Saizen, Proleukin, Leukine
Imperial College London
HIV-1
 
 
2007-000934-38: Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients to Prevent Recurrence

Ongoing
2
80
Europe
HER2/neu, 654-661, Ii-key modified HER2/neu, 776-790, GP2, AE37, Leukine, Leukine
Generex Biotechnology Corporation
Disease-free, conventionally treated node-positive and high-risk node-negative breast cancer patients who are at significant risk for recurrence.
 
 
2015-003186-28: BIOSKILL: Studying Vacc-4x, an HIV therapeutic vaccine, an as-sessment of immune-mediated anti-viral effects, when administered with adjuvant GM-CSF prior to HIV latent reservoir activation by the HDAC inhibitor, romidepsin

Ongoing
2
192
Europe
Vacc-4x, Leukine, Istodax, Vacc-4x, -, Powder for solution for injection, Powder and solution for solution for injection, Leukine, Istodax
Bionor Pharma ASA, Bionor Pharma ASA
HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02]
 
 
VADIS, NCT02636582: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Completed
2
43
US
Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, E75 Plus GM-CSF, E75 Vaccine Plus GM-CSF, HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF, Nelipepimut-S Plus Sargramostim, NeuVax Plus GM-CSF, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
National Cancer Institute (NCI)
Breast Ductal Carcinoma In Situ
07/19
05/23
NCI-2015-00694, NCT02455557: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Active, not recruiting
2
66
US
Laboratory Biomarker Analysis, Montanide ISA 51 VG, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
Roswell Park Cancer Institute
Glioblastoma, Gliosarcoma
10/19
12/24
2019-002026-75: Clinical research study to investigate effectiveness and safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma

Not yet recruiting
2
154
Europe, RoW
UV1, LEUKINE, Powder for solution for injection
Ultimovacs ASA, Ultimovacs ASA
Unresectable or Metastatic Melanoma, A melanoma not capable of being surgically removed or that has been spread to other parts of the body, Diseases [C] - Cancer [C04]
 
 
NCT02484443: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

Completed
2
41
Canada, US, RoW
Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
03/20
09/23
2019-002721-30: Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)

Ongoing
2
118
Europe
Yervoy, Opdivo, UV1, Leukine, BMS-936558, Infusion, Powder and solvent for solution for injection, Yervoy (ipilimumab), Opdivo (nivolumab), Leukine
Oslo University Hospital, BMS Pharmaceuticals Ltd, Ultimovacs
Malignant pleural mesothelioma (MPM), Malignant pleural mesothelioma (MPM), Diseases [C] - Cancer [C04]
 
 
2020-005910-17: Phase II study of pembrolizumab alone or in combination with UV1 cancer vaccine in patients with recurrent or metastatic PD-L1-positive (CPS≥1) head and neck squamous cell carcinoma. Phase-II-Studie mit Pembrolizumab allein oder in Kombination mit dem UV1-Krebsimpfstoff bei Patienten mit rezidiviertem oder metastasiertem PD-L1-positivem (CPS≥1) Plattenepithelkarzinom im Kopf- Hals-Bereich

Not yet recruiting
2
75
Europe
UV-1, Powder for solution for injection, Lyophilisate for solution for injection, Leukine
Martin-Luther-Universität Halle-Wittenberg, Ultimovacs ASA
Recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Rezidiviertes oder metastasiertes Plattenepithelkarzinom des Kopf-Hals Bereiches (HNSCC), Recurrent or metastatic head and neck squamous cell carcinoma. Rezidiviertes oder metastasiertes Plattenepithelkarzinom des Kopf Hals Bereichs (HNSCC), Diseases [C] - Cancer [C04]
 
 
2020-004738-39: DOVACC.A study investigating the effect of the medication: olaparib, durvalumb and UV1 as maintenance therapy for patients with Recurrent Ovarian Cancer.

Ongoing
2
184
Europe
UV1, Imfinzi (Durvalumab), LEUKINE, Powder for solution for injection, Tablet, Infusion, Lynparza, Imfinzi, Leukine
Nordic Society of Gynaecological Oncology - Clinical Trial Unit, Ultimovacs, AstraZeneca
Ovarian cancer, Ovarian cancer, Diseases [C] - Cancer [C04]
 
 
NCT01857934: Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting
2
153
US
cyclophosphamide, Cytoxan(R), topotecan, Hycamtin(R), hu14.18K322A, humanized anti-GD2 antibody, monoclonal antibody, dinutuximab, peripheral blood stem cell harvest, PBSCH, surgical resection, cisplatin, Platinol-AQ(R), etoposide, VP16, Vepesid(R), Etopophos(R), doxorubicin, Adriamycin(R), vincristine, Oncovin(R), busulfan, Busulfex(R), melphalan, L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin, Alkeran(R), peripheral blood stem cell transplantation, PBSCT, natural killer cell infusion, NK cell infusion, radiation therapy, GM-CSF, sargramostim, Leukine(R), granulocyte macrophage colony stimulating factor, G-CSF, Granulocyte colony stimulating factor, Neupogen(R), Filgrastim, mesna, Mesnex(R), levetiracetam, Keppra, interleukin-2, IL-2, aldesleukin, Proleukin(R), Isotretinoin, 13-cis retinoic acid, CliniMACS, Cell Selection System
St. Jude Children's Research Hospital, Cookies for Kids' Cancer, CURE Childhood Cancer, Inc.
Neuroblastoma
10/21
12/24
NCI-2018-03732, NCT03786783: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active, not recruiting
2
42
US, RoW
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dexrazoxane, 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI), 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI), ADR-529, ICRF-187, Razoxane (+)-form, Soluble ICRF (L-isomer), Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Topotecan, Hycamptamine, Topotecan Lactone, Vincristine, LCR, Leurocristine, VCR, Vincrystine
National Cancer Institute (NCI)
Ganglioneuroblastoma, High Risk Neuroblastoma
12/21
09/24
2021-005729-25: A trial to investigate UVT vaccine in combination with standard immunotherapy treatment vs standard immunotherapy treatment alone, fortreatment of patients with non-small cell lung cancer.

Not yet recruiting
2
138
Europe
UV1, Leukine, Powder and solution for solution for injection, Leukine
Vestre Viken Health Trust, Ultimovacs
Inoperable advanced or metastatic non-small cell lung cancer (NSCLC), Inoperable advanced or metastatic non-small cell lung cancer (NSCLC), Diseases [C] - Cancer [C04]
 
 
NCT03012100: Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Active, not recruiting
2
280
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, FR Alpha Peptide Vaccine, Placebo Administration, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
08/22
07/26
NCI-2018-01474, NCT03600350: pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

Active, not recruiting
2
19
US
pTVG-HP, Nivolumab, Opdivo, GM-CSF, Leukine, Sargramostim
University of Wisconsin, Madison, Bristol-Myers Squibb, Madison Vaccines Inc. (MVI), AIQ Solutions
Prostate Cancer
12/22
11/24
NCT01903330: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Checkmark Interim results in combination with ERC1671/GM CSF/cyclophosphamide for recurrent glioblastoma
Aug 2020 - Aug 2020: Interim results in combination with ERC1671/GM CSF/cyclophosphamide for recurrent glioblastoma
Active, not recruiting
2
84
US
ERC1671, Gliovac, GM-CSF, Leukine®, sargramostim, Cyclophosphamide, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar, Avastin, MVASI, bevacizumab-awwb, bevacizumab-bvzr, ZIRABEV
Epitopoietic Research Corporation, University of California, Irvine
Glioblastoma, Gliosarcoma
03/23
03/23
ANBL19P1, NCT04385277: Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Active, not recruiting
2
34
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, FDG-Positron Emission Tomography, FDG, FDG-PET, FDG-PET Imaging, Iobenguane I-123, AdreView, iobenguane I 123, Irinotecan, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Nodular, Neuroblastoma
06/23
09/24
Conerstone3, NCT05771584: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

Recruiting
2
24
RoW
AST-301, pNGVL3-hICD, rhuGM-CSF, Leukine, Sargramostim
Aston Sci. Inc.
Gastric Cancer
10/23
06/26
NCT04739618: Metastatic Solid Cancer Clinical Trial

Recruiting
2
32
US
Keytruda Injectable Product, pembrolizumab, Yervoy Injectable Product, ipilimumab, GM-CSF, sargramostim, Non-ablative Cryosurgical freezing
ImmunSYS, LLC
Metastatic Cancer
12/23
12/23
ABSCOPAL 5001, NCT04713371: A Phase 2 Trial for Patients With Metastatic Solid Cancer

Active, not recruiting
2
32
US
Keytruda Injectable Product, pembrolizumab, Yervoy Injectable Product, ipilimumab, Cytoxan, Cyclophosphamide, Cryosurgical freezing (cryosurgery), Cryoablation, GM-CSF Injectable, Sargramostim
Rampart Health, L.L.C.
Metastatic Cancer
12/24
12/24
NCT05242965: A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

Recruiting
2
40
US
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, CD105/Yb-1/SOX2/CDH3/MDM2 Plasmid Vaccine, STEMVAC, STEMVAC Th1 Polyepitope Plasmid-based Vaccine, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Computed Tomography, CAT Scan, Computed Axial Tomography, CT Scan, Biopsy, Bx, Biospecimen Collection, Biological Sample Collection
University of Washington, United States Department of Defense
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
12/25
12/26
NIPU, NCT04300244: Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

Hourglass Jul 2022 - Dec 2022 : Top-line data from NIPU trial in combination with UV1 and Yervoy for malignant mesothelioma
Active, not recruiting
2
118
Europe, RoW
UV1 vaccine + leukine, ipilimumab, Yervoy, nivolumab, Opdivo
Åslaug Helland, Oslo University Hospital, Ultimovacs ASA, Bristol-Myers Squibb
Cancer, Cancer, Lung, Cancer of Lung, Mesothelioma, Mesothelioma; Lung, Mesothelioma; Pleura, Mesotheliomas Pleural
03/25
03/27
INITIUM, NCT04382664: UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Hourglass Jul 2022 - Dec 2022 : Top-line data from INITIUM trial in combination with UV1 and Yervoy for 1L melanoma
Completed
2
156
Europe, US
UV1, Sargramostim, Leukine, Ipilimumab, Yervoy, Nivolumab, Opdivo
Ultimovacs ASA
Malignant Melanoma
01/24
04/24
NCT05455658: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Recruiting
2
33
US
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, CD105/Yb-1/SOX2/CDH3/MDM2 Plasmid Vaccine, STEMVAC, STEMVAC Th1 Polyepitope Plasmid-based Vaccine, Sargramostim, 123774-72-1, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
University of Washington, National Cancer Institute (NCI), University of Wisconsin, Madison
Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
04/25
12/25
RESURGe, NCT04013672: Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Active, not recruiting
2
40
US
Pembrolizumab, SurVaxM, SVN53-67, M57-KLH, Sargramostim, GM-CSF, Montanide ISA 51
David Peereboom
Recurrent Glioblastoma
05/24
05/24
NCT04856176: A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Recruiting
2
83
US
Granulocyte-Macrophage Colony-Stimulating Factor, Pembrolizumab, pemetrexed, Paclitaxel, Carboplatin
Tufts Medical Center, Partner Therapeutics, Inc.
Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4
12/24
12/24
NCT04237623: GM-CSF With Post-Transplant Cyclophosphamide

Recruiting
2
38
US
Sargramostim, GM-CSF, Control Arm, G-CSF
Northside Hospital, Inc.
Transplant-Related Hematologic Malignancy
09/24
09/25
NCT04703426: Sargramostim (GM-CSF) + PD-1

Withdrawn
2
30
NA
Sargramostim (GM-CSF), Leukine, Pembrolizumab (anti-PD-1), Keytruda
Dana-Farber Cancer Institute, Partner Therapeutics (PTx)
Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
06/24
06/25
NCT03794349: Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Active, not recruiting
2
95
Canada, US, RoW
Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Eflornithine Hydrochloride, alpha-Difluoromethylornithine hydrochloride, Eflornithine.HCl, Iwilfin, MDL 71782, Ornidyl, RMI-71782, Vaniqa, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
Children's Oncology Group, National Cancer Institute (NCI)
High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
03/25
03/25
SESAD, NCT04902703: Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

Recruiting
2
42
US
Sargramostim, Leukine, Granulocyte Macrophage Colony Stimulating Factor, Saline - placebo comparator, Sterile solution of sodium chloride in water
University of Colorado, Denver, National Institute on Aging (NIA), Alzheimer's Association, Partner Therapeutics, Inc.
Alzheimer Disease
07/25
07/25
NCT06450041: NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Not yet recruiting
2
62
US
Universal Donor (UD) TGFβi NK Cells, Temozolomide, Irinotecan, Dinutuximab, Unituxin, GM-CSF, Sargramostim
New Approaches to Neuroblastoma Therapy Consortium, Nationwide Children's Hospital, United Therapeutics, Children's Neuroblastoma Cancer Fund
Neuroblastoma
12/28
12/38
NCT06202066: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Not yet recruiting
2
132
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Incomplete Freund''s Adjuvant, Freund's Incomplete Adjuvant, IFA, incomplete Freund's adjuvant, ISA-51, Montanide ISA 51, Montanide ISA-51, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, SVN53-67/M57-KLH Peptide Vaccine, SurVaxM, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
Roswell Park Cancer Institute
Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm, Pancreatic Neuroendocrine Neoplasm
01/27
01/28
FOCUS, NCT05075122 / 2020-005910-17: Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

Recruiting
2
75
Europe
UV1, Sargramostim for Injection, Pembrolizumab injection
Martin-Luther-Universität Halle-Wittenberg, Ultimovacs ASA, Apotheke der Universitätsmedizin der Johannes Gutenberg-Universität Mainz (Germany), Axel Hinke. CCRC Cancer Clinical Research Consulting (Düsseldorf, Germany
Head and Neck Squamous Cell Carcinoma
08/24
02/25
GPAD-3, NCT03304821: Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

Recruiting
2
176
US
GM-CSF, Sargramostim, Leukine, Placebo
Emory University, National Heart, Lung, and Blood Institute (NHLBI)
Peripheral Artery Disease (PAD)
10/24
10/24
NCT05754684: Quadruple Immunotherapy for Neuroblastoma

Recruiting
2
29
RoW
Natural killer cell, NK cell, Dinutuximab beta, Ch14.18, Interleukin-2, Aldesleukin, Granulocyte-Macrophage Colony-Stimulating Factor, Sargramostim, Spironolactone, Aldactone, Naxitamab, hu3F8
Hong Kong Children's Hospital, The University of Hong Kong
Neuroblastoma Recurrent
12/24
12/25
ACCRU-BR-1701, NCT04197687: TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Recruiting
2
480
US
Multi-epitope HER2 Peptide Vaccine TPIV100, HER2/Neu Peptide Vaccine TPIV100, Peptide Vaccine TPIV100, TPIV 100, TPIV-100, TPIV100, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Placebo Administration, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
01/25
01/25
LUNGVAC, NCT05344209: Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

Recruiting
2
138
Europe
UV1, Sagramostim, leukine, Anti-PD-1/PD-L1 treatment
Vestre Viken Hospital Trust, University Hospital, Akershus, Oslo University Hospital, Haukeland University Hospital, Helse Stavanger HF, Helse Fonna, Helse Nord-Trøndelag HF, St. Olavs Hospital, Alesund Hospital, Helse Forde, University Hospital of North Norway
Oncology, NSCLC Stage IV, NSCLC, Stage III
07/25
07/27
Cornerstone001, NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Terminated
2
10
US, RoW
AST-301(pNGVL3-hICD), AST-301, rhuGM-CSF, Leukine, Sargramostim, Placebo, Normal Saline, Pembrolizumab, Keytruda, Capecitabine, Xeloda
Aston Sci. Inc.
Breast Cancer
05/24
05/24
Cornerstone4, NCT05794659: Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

Not yet recruiting
2
98
US
AST-201, pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo, Normal saline (USP), rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor), sargramostim, Leukine
Aston Sci. Inc.
Advanced Ovarian Cancer
11/25
11/27
NCT05482334: Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

Recruiting
2
42
US
Sargramostim for Injection, Leukine, Granulocyte Macrophage Colony Stimulating Factor, Saline Placebo, Bacteriostatic Saline
University of Colorado, Denver, National Institute on Aging (NIA)
Down Syndrome
09/26
09/26
2010-020435-40: Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanoma

Ongoing
1/2
21
Europe
MAGE-3.A1, NA17.A2 peptide, MAGE-3.A1, NA17.A2, Powder for suspension for injection, Powder for solution for injection, Powder and solvent for solution for injection, Cream, Solution for injection, Proleukine®, Leukine®, Aldara®, IntronA®
Centre du Cancer
metastatic melanoma patients with regional disease (any T; N2c or N3; M0) or with distant metastatic disease ( any T; any N; M1a, M1b or M1c), except uncontrolled brain or CNS metastases, and elevated LDH (superior to 1,5 times the upper normal value)
 
 
NCT01297478: Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, Prednisone, Rituximab, Pegfilgrastim, and Sargramostim as Front-Line Therapy in Treating Patients With Aggressive Non-Hodgkin Lymphoma

Recruiting
1/2
60
US
pegfilgrastim, rituximab, sargramostim, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, R-CHOP regimen, external beam radiation therapy
Auxilio Mutuo Cancer Center
Lymphoma
04/11
 
NCT01789099 / 2012-001852-20: A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.

Active, not recruiting
1/2
18
Europe
UV1 synthetic peptide vaccine and GM-CSF, UV1, Leukine
Ultimovacs ASA, Oslo University Hospital
Non-small Cell Lung Cancer
04/23
04/23
NCT01784913 / 2012-002411-26: A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

Active, not recruiting
1/2
22
Europe
UV1 synthetic peptide vaccine and GM-CSF, UV1, Leukine
Ultimovacs ASA
Prostate Cancer
04/23
04/23
STING, NCT04211675: NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Recruiting
1/2
31
US
Natural Killer Cells, Temozolomide, Temodar, Irinotecan, Camptosar, Dinutuximab, Sargramostim, Leukine
Nationwide Children's Hospital
Relapsed Neuroblastoma, Refractory Neuroblastoma
12/24
12/25
PNeoVCA, NCT05269381: Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Recruiting
1/2
36
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Neoantigen Peptide Vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
Mayo Clinic
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Cervical Carcinoma, Locally Advanced Endometrial Carcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Skin Squamous Cell Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Cervical Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma
02/25
02/26
NCT02275416: Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Checkmark From positive 5-year overall survival data in combination with UV1 for metastatic malignant melanoma
Dec 2020 - Dec 2020: From positive 5-year overall survival data in combination with UV1 for metastatic malignant melanoma
Active, not recruiting
1/2
12
Europe
Ipilimumab, Yervoy, UV1 vaccine, UV1, GM-CSF, Leukine
Ultimovacs ASA, Oslo University Hospital
Malignant Melanoma
02/25
02/25
NCT05101356: A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Recruiting
1/2
77
US
Antineoplastic Vaccine, cancer treatment vaccine, Cancer Vaccine, Neoplasm Vaccine, Tumor Vaccine, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Pembrolizumab, KEYTRUDA, MK-3475
Tianhong Li, National Cancer Institute (NCI), LabyRx Immunologic Therapeutics
Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm
01/26
01/30
NCT00436254: Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Active, not recruiting
1
66
US
pNGVL3-hICD vaccine, sargramostim, GM-CSF, granulocyte macrophage colony-stimulating factor, Leukine, Prokine, rhu GM-CFS, flow cytometry, immunologic technique, immunological laboratory methods, laboratory methods, immunological, immunoenzyme technique, immunoenzyme techniques, protein expression analysis, biopsy, biopsies
University of Washington, National Cancer Institute (NCI)
HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
03/10
12/24
NCT00887796: Decitabine, Vaccine Therapy, and Doxorubicin Hydrochloride Liposome in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Active, not recruiting
1
18
US
NY-ESO-1 peptide vaccine, incomplete Freund's adjuvant, sargramostim, decitabine, pegylated liposomal doxorubicin hydrochloride, DNA methylation analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry
Roswell Park Cancer Institute
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
10/11
 
NCT02444546: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Completed
1
6
US
Laboratory Biomarker Analysis, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Wild-type Reovirus, Reolysin
Mayo Clinic, National Cancer Institute (NCI)
Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
07/18
11/22
WOKVAC, NCT03156309: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

Recruiting
1
30
US
Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, pUMVC3-IGFBP2-HER2-IGF1R, pUMVC3-IGFBP2-HER2-IGF1R Vaccine, WOKVAC, WOKVAC Vaccine, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI), University of Wisconsin, Madison
HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
12/19
 
NCT00669734: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Active, not recruiting
1
18
US
Falimarev, fCEA-MUC-1-TRI, Fowlpox-CEA(D609)-MUC1(L93)-TRICOM Vaccine, Fowlpox-CEA-MUC-1-TRICOM, PANVAC-F, recombinant fowlpox-CEA-MUC-1-TRICOM vaccine, rFowlpox-CEA(D609)/MUC1(L93)/TRICOM Vaccine, Inalimarev, PANVAC-V, recombinant vaccinia-CEA-MUC-1-TRICOM vaccine, rVaccinia-CEA(D609)/MUC1(L93)/TRICOM Vaccine, Vaccinia-CEA-MUC1-TRICOM Vaccine, Laboratory Biomarker Analysis, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
09/21
04/25
NCT02334865: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Active, not recruiting
1
18
US
Incomplete Freund's Adjuvant, Freund's Incomplete Adjuvant, IFA, ISA-51, Montanide ISA 51, Montanide ISA-51, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, SVN53-67/M57-KLH Peptide Vaccine
Roswell Park Cancer Institute, Celgene
Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
09/22
05/26
NCT03332667: MIBG With Dinutuximab +/- Vorinostat

Active, not recruiting
1
45
US
131I-MIBG, 131I-Metaiodobenzylguanidine, Iobenguane sulfate, m-Iodobenzylguanidine sulfate, MIBG, Dinutuximab, Chimeric Monoclonal Antibody 14.18, MAB Ch 14.18, Unituxin, Ch14.18, Vorinostat, Zolina, Sargramostim, Potassium Iodide
New Approaches to Neuroblastoma Therapy Consortium, United Therapeutics
Neuroblastoma
06/23
06/24
NCT03790670: Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

Active, not recruiting
1
7
US
sargramostim, Leukine
University of Nebraska
Parkinson Disease
10/24
12/24
NCT05475106: Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms

Recruiting
1
100
RoW
Neoantigen Peptides
Instituto de Medicina Regenerativa
Neoplasms
11/25
06/26
NCT03879694: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Recruiting
1
14
US
Incomplete Freund's Adjuvant, Freund's Incomplete Adjuvant, IFA, ISA-51, Montanide ISA 51, Montanide ISA-51, Octreotide Acetate, D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt), Longastatin, Longastatina, Samilstin, Sandostatin, Sandostatin Lar Depot, Sandostatina, Sandostatine, SMS 201-995, SMS 201-995 AC, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, SVN53-67/M57-KLH Peptide Vaccine
Roswell Park Cancer Institute, NeuroEndocrine Tumor Research Foundation (NETRF)
Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor
12/24
12/25
NCT05677633: Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease

Active, not recruiting
1
11
US
Sargramostim, Leukine
University of Nebraska, Partner Therapeutics, Inc.
Parkinson's Disease and Parkinsonism
04/24
12/24
NCT03189706: Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Active, not recruiting
1
48
US
Irinotecan, temozolomide, Hu3F8, GM-CSF
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma (NB)
06/25
06/25
NCT04040231: Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Active, not recruiting
1
10
US
Galinpepimut-S, Nivolumab, Sargramostim, GM-CSF
Memorial Sloan Kettering Cancer Center
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
07/24
07/24
NCT05717140: Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Not yet recruiting
1
24
US
Aerosol Sargramostim, Aerosol GM-CSF, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Mayo Clinic
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
04/25
04/25
WOKVAC, NCT02780401: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

Active, not recruiting
1
24
US
Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, pUMVC3-IGFBP2-HER2-IGF1R, pUMVC3-IGFBP2-HER2-IGF1R Vaccine, WOKVAC, WOKVAC Vaccine, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
University of Washington, National Cancer Institute (NCI), University of Wisconsin, Madison
HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
03/25
03/25

Download Options